When it Comes to First Launches, Can Two Heads Be Better Than One?

Posted by Andy Singley on Thu, Mar 05, 2020

Judith Kulich, Ben Hohn and Cody Powers contributed to this blog post.

In recent years, we have seen an uptick in the number of “first launches”—defined by ZS as a company’s first marketed asset with FDA “novel” status. While earlier in the decade we saw just a handful of first launches each year, over the past three years we’ve seen the rate of first launches roughly double that. More pre-commercial companies are choosing to take their assets all the way to market compared to earlier in the decade.


>
Read More

Predicting Drugs' Commercial Potential: No Crystal Ball Yet, but Can We Get Closer to One?

Posted by Yasasvi Popuri on Wed, Feb 05, 2020

Emily Mandell co-wrote this blog post with Yasasvi Popuri.

What clinical profile should our pipeline drug pursue to compete in a crowded market? For which patients will our drug be preferred and why? How will the adoption of our in-market drug change with upcoming biosimilars, competitive launches and changing guidelines? These multibillion-dollar questions are very familiar to commercial and medical teams of pharmaceutical and biotech companies, but just how do they feel about answering them? Simply put: uncertain.


>
Read More

What China’s Latest Drug Negotiations Mean for Global Pharma Companies

Posted by Crystal Lam on Wed, Jan 22, 2020

Sonia Yan and Daniel Blessing co-authored this blog post with Crystal Lam.

China’s National Healthcare Security Administration (NHSA) recently released the outcomes of its 2019 National Reimbursed Drug List (NRDL) negotiations: 70 of 119 new therapies were successfully listed. This record outcome more than doubled the number of therapies reimbursed through China’s negotiation pathway, which was formally implemented in 2017.


>
Read More

The Keys to Successful Digital Therapeutics Commercialization

Posted by Pete Masloski on Wed, Jan 08, 2020

One of the more exciting areas in the world of digital health is a subset of solutions known as digital therapeutics, or DTx. The Digital Therapeutics Alliance defines them as “software-based solutions used by patients and their caregivers or providers that are clinically validated where their use leads to a tangible improvement in health outcomes.” Pear Therapeutics, Propeller Health and Voluntis are a few of the pioneering companies that have introduced DTx solutions. Many DTx solutions implement an established behavioral or physical therapy with software tailored to each patient. Others use video games or virtual reality to alleviate pain or address ADHD.


>
Read More

Accelerating Market Access: Three Trends Shaping Pharma’s Future

Posted by Ed Schoonveld on Mon, Jan 06, 2020

Dean Hakanson co-wrote this blog post with Ed Schoonveld. This blog post was originally published on The Price of Global Health.

Is the demand for value-based care merely superficial? Are the industry’s decision-making and incentive systems built to encourage clinical innovation? How will pharma companies rethink their pipelines to improve poor commercialization efforts?


>
Read More